Skip to main content

Closed

HALO: Halozyme Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+22.4% / yr

Operating margin57.0%

ROIC23.6%

Financially safe

Strong

Debt / equity9.76×

Interest coverage45.0×

Current ratio2.76×

Valuation

Unrated

P/E ratio28.5×

Halozyme Therapeutics, Inc.

HALONASDAQ Global Select·USD·Closed

Halozyme Therapeutics, Inc.

HALONASDAQ·USD·Closed

$82.54

−0.91%

$82.54

−$0.76 (0.91%)

52W Range

93thpctl

Volume

0.81×avg

Mkt Cap

9.79BUSD

P/E

28.5TTM

Div Yield

–ann

52W Range

93thpctl

Volume

0.81×avg

Market Cap

9.79BUSD

P/E Ratio

28.5TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings